Jaguar Health Overview
- Founded
- 2013
- Status
- Public
- Employees
- 34
- Stock Symbol
- JAGX
- Investments
- 1
- Share Price
- $0.38
- (As of Monday Closing)
Jaguar Health General Information
Description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.
Contact Information
Website
www.jaguar.health
Formerly Known As
Jaguar Animal Health
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 200 Pine Street
- Suite 400
- San Francisco, CA 94104
- United States
+1 (415) 000-0000
Jaguar Health Timeline
Jaguar Health Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.38 | $0.40 | $0.37 - $7.44 | $20.4M | 51.1M | 3.69M | -$0.78 |
Jaguar Health Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
|---|---|---|---|---|
| EV | 109,073 | 101,260 | 32,906 | 159,242 |
| Revenue | 4,831 | 9,385 | 5,775 | 4,416 |
| EBITDA | (38,205) | (28,737) | (30,870) | (28,198) |
| Net Income | (47,051) | (33,809) | (38,539) | (32,146) |
| Total Assets | 59,255 | 42,843 | 36,410 | 41,042 |
| Total Debt | 27,830 | 16,210 | 7,565 | 16,085 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Jaguar Health Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Jaguar Health‘s full profile, request access.
Request a free trialJaguar Health Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Jaguar Health‘s full profile, request access.
Request a free trialJaguar Health Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, an
Pharmaceuticals
San Francisco, CA
34
As of 2020
000.00
000000000
000.00
0000000
ercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehe
000000000000000
The Woodlands, TX
00
As of 0000
00000
000000000
00000
000000 0
dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco la
000000000000000
Laval, Canada
00000
As of 0000
000.00
000000000
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialJaguar Health Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals | Corporation | The Woodlands, TX | 00 | 00000 | 000000000 | 00000 |
| 000000 000000 0000 | Corporate Backed or Acquired | Laval, Canada | 00000 | 000.00 | 000000000 | 000.00 |
Jaguar Health Patents
Jaguar Health Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20180021297-A1 | Use of croton- or calophyllum-derived proanthocyanidin polymers or botanical extracts in combination with rifaximin for the treatment of diarrhea in non-human animals | Abandoned | 26-Feb-2015 | 0000000000 | |
| US-20180028490-A1 | Methods of treating diarrhea and promoting intestinal health in non-human animals | Abandoned | 26-Feb-2015 | 0000000000 | |
| CA-2976945-A1 | Methods of treating diarrhea and promoting intestinal health in non-human animals | Abandoned | 26-Feb-2015 | 0000000000 | |
| AU-2016222791-A1 | Methods of treating diarrhea and promoting intestinal health in non-human animals | Abandoned | 26-Feb-2015 | 0000000000 | |
| US-20180264061-A1 | Methods of treating diarrhea in companion animals | Abandoned | 09-Jan-2015 | A61K36/47 |
Jaguar Health Executive Team (18)
Jaguar Health Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| James Bochnowski | Self | Chairman & Board Member | 000 0000 |
| John Micek | Self | Board Member | 000 0000 |
| Jonathan Siegel | Self | Board Member | 000 0000 |
| Lisa Conte | Jaguar Health | Founder, Chief Executive Officer, President & Board Member | 000 0000 |
| Murray MacNaughtan | Jaguar Health | Board Member | 000 0000 |
Jaguar Health Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialJaguar Health Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Jaguar Health‘s full profile, request access.
Request a free trialJaguar Health Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000 00000000 | 31-Jul-2017 | 0000000000 | Drug Discovery | 0000 0000 |
Jaguar Health Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 0000 0000000000000 | Drug Discovery | San Francisco, CA | 0000 |